Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report

Publisher： Karger

E-ISSN： 1661-3805|12|1|45-47

ISSN： 1661-3791

Source： Breast Care, Vol.12, Iss.1, 2017-02, pp. : 45-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 424-426

Karger

Access to resources Recommend Favorite

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 78-84

Karger

Access to resources Recommend Favorite

Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 168-171

Karger

Access to resources Recommend Favorite

Therapy Standards in HER2-Positive Breast Cancer

By  

Breast Care, Vol. 11, Iss. 2, 2016-04 ,pp. : 148-150

Karger

Access to resources Recommend Favorite

Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study

By  

Breast Care, Vol. 2, Iss. 4, 2007-08 ,pp. : 227-233

Karger

Access to resources Recommend Favorite